Literature DB >> 2294998

Proliferative properties of unfractionated, purified, and single cell human progenitor populations stimulated by recombinant human interleukin-3.

G Kannourakis1, G R Johnson.   

Abstract

In this report, the biological properties of human recombinant interleukin-3 (rhIL-3) were studied. We investigated the range of unfractionated, purified and single cell human progenitors responsive to IL-3; compared the colony types observed with those obtained in the presence of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) or granulocyte-CSF (G-CSF). The results show that IL-3 directly stimulates the formation of colonies derived from eosinophil and, to a lesser degree, granulocyte and macrophage progenitors. In combination with erythropoietin, it supports the development of erythroid and mixed-erythroid colonies. Furthermore, the data show that IL-3 is a more potent stimulus for both erythroid and eosinophil progenitors than GM-CSF. Interleukin-3 stimulates the formation of both compact and dispersed colonies derived from eosinophil progenitors, whereas GM-CSF stimulates the formation of only the compact type. We conclude that some of the proliferative effects of IL-3 observed on unfractionated and semipurified bone marrow populations are indirect and most likely involve accessory cell interactions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2294998

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Combination of recombinant cytokines fails to produce ex vivo expansion of human blood hematopoietic progenitor cells.

Authors:  Y Takaue; T Abe; Y Kawano; A Hirao; A Yokobayashi; Y Okamoto; S Saito; T Shimizu; J Sato; T Watanabe
Journal:  Ann Hematol       Date:  1992-05       Impact factor: 3.673

2.  Differential effects of microenvironmentally presented interleukin 3 versus soluble growth factor on primitive human hematopoietic cells.

Authors:  T Otsuka; J D Thacker; C J Eaves; D E Hogge
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

Review 3.  Why clinicians should be interested in interleukin-3.

Authors:  P Valent; K Geissler; C Sillaber; K Lechner; P Bettelheim
Journal:  Blut       Date:  1990-12

4.  Granulocyte-macrophage colony-stimulating factor and interleukin-3 in combination: a potent and consistent myelodysplastic syndrome bone marrow stimulant in vitro.

Authors:  Z Estrov; R Kurzrock; M Talpaz; M Blake; J U Gutterman
Journal:  Ann Hematol       Date:  1991-12       Impact factor: 3.673

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.